Loading data for FULC — first visit, this takes a few seconds.
Fulcrum Therapeutics, Inc. (FULC)
NasdaqGM: FULC
· 即時價格 · USD
3.85
+0.01 (0.26%)
收盤價： Sep 11, 2026, 8:00 PM
3.80
+0.00%
盤後: 4:10 PM
股價、關鍵數字和最新消息，都在這一頁。
Fulcrum Therapeutics, Inc.（FULC）股價、分析與資料
無可用資料
| 買價 | 2.71 |
| 市值 | 290M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -85M |
| 2.58 | |
| -1.21 | |
| n/a | |
| -7.79 | |
| P/B (ttm) | 0.93 |
| P/S (ttm) | 0.00 |
| 財報日期 | Oct 29, 2026 |
| 賣價 | 4.78 |
| 成交量 | 1,004,738 |
| 20 日平均成交量 | 2,208,642 |
| 開盤價 | 3.81 |
| 前收盤價 | 3.84 |
| 當日區間 | 3.80 - 3.85 |
| 52 週範圍 | 2.83 - 15.74 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the tr...
完整的公司簡介財報驚奇
Fulcrum Therapeutics 已於 Jul 30, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -0.22 低於預期 0.00, 年增 21.43% 成長.
第 1 頁，共 2 頁